RxDoctor Payments Data

Angela Kalem, APRN

Psychiatric/Mental Health · Spokane, WANPI 1265020002

Payments from drug & device makers

$2,605in general payments, 2019–2025

Across 169 payments — averaging $15.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$361
  • Otsuka America Pharmaceutical, Inc.$215
  • Teva Pharmaceuticals USA, Inc.$162
  • Lundbeck LLC$104
  • Vanda Pharmaceuticals Inc.$93
  • plus $513 from 10 others

What the payments were for

  • Food & beverage$2,55898%
  • Education$472%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,605 in reported general payments places this provider in the 85th percentile of 931 psychiatric/mental health providers in Washington.

See all psychiatric/mental health providers in Washington

Medicare billing

Part B allowed, 2024
$14,661
Medicare patients
30
Services billed
184

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine12$72,878
Quetiapine Fumarate27$2,216
Quetiapine Fumarate ErQuetiapine Fumarate18$1,496
Bupropion XlBupropion Hcl30$767
Duloxetine Hcl40$662
Alprazolam68$548
Clonazepam45$436
Dextroamphetamine Sulfate11$421
Lamotrigine25$337
Lurasidone Hcl11$285
Trazodone Hcl19$279
Temazepam24$262
Benztropine Mesylate22$222
Gabapentin13$205
Buspirone Hcl26$197

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$162$72,87812 claims
Almatica Pharma LLCSertraline Hcl$73$18335 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 931 psychiatric/mental health providers in Washington.

Other psychiatric/mental health in Spokane

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →